A
B
C
D
E
F
G
H
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

C

蔡修宇
蔡修宇
中山大学肿瘤防治中心
播放:210
前沿聚焦——免疫营养与肿瘤微环境正常化
播放:51
中国临床肿瘤学年度进展2021（鼻咽癌）
陈守臻
陈守臻
山东大学齐鲁医院
播放:8
Abstract ID: 5006 Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
播放:1
Abstract ID: 5005 A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
播放:3
Abstract ID: 5000 TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603).
陈晓锋
陈晓锋
南京医科大学第一附属医院
播放:45
中国临床肿瘤学年度进展2021（肠癌）
陈晓钟
陈晓钟
浙江省肿瘤医院
播放:27
“双安”联合——探索派安普利单抗联合安罗替尼在复发转移鼻咽癌的应用
陈漪
复旦大学附属中山医院
播放:7
践行指南-一例达贝方案治疗晚期HCC
陈誉
陈誉
福建省肿瘤医院
播放:15
Abstract ID: 9508 A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral me
播放:8
Abstract ID: 9505 Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047
播放:8
Abstract ID: LBA 9500 Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study.
程颖
程颖
吉林省肿瘤医院
播放:102
Current Standard Practice after ASCO 2022: 肺 癌

D

段建春
段建春
中国医学科学院肿瘤医院
播放:120
CHOICE-01研究更新解读

G

葛睿
葛睿
复旦大学附属华东医院
播放:76
中国临床肿瘤学年度进展2021（乳腺癌）
贡铁军
贡铁军
哈尔滨血液病肿瘤研究所
播放:4
Abstract ID: 8001 ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
播放:13
Abstract ID: LBA4 Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
顾仰葵
顾仰葵
中山大学肿瘤医院
播放:36
双艾肝癌系统治疗的光辉之路
郭洪波
郭洪波
山东省肿瘤医院
播放:158
特瑞普利单抗在新辅助治疗中的最新进展

H

郝春芳
郝春芳
天津肿瘤医院
播放:9
Abstract ID: 1005 Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free surviva
播放:9
Abstract ID: LBA1004 A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone recep
播放:3
Abstract ID: 507 Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.

J

景红梅
景红梅
北京大学第三医院
播放:30
阿可替尼在MCL及其它血液肿瘤的最新进展

L

李恩孝
李恩孝
西安交通大学医学院第一附属医院
播放:19
专家评述
李际盛
李际盛
山东大学齐鲁医院
播放:53
循证指引——免疫营养素作用机制
李娟
中国人民解放军总医院
播放:24
病例展示（三）
李宁
李宁
中国医学科学院肿瘤医院
播放:17
Abstract ID: 5502 Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis.
播放:11
Abstract ID: LBA5500 ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer
李伟
李伟
苏州大学附属第一医院
播放:9
病例展示（一）
梁军
梁军
北大国际医院
播放:12
播放:2
刘磊
刘磊
四川大学华西医院
播放:6
Abstract ID: 6005 ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC).
播放:4
Abstract ID: 6004 An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
刘联
刘联
山东大学齐鲁医院
播放:157
地舒单抗在实体瘤骨转移中的应用进展
播放:214
从CSCO指南更新看胃癌一线治疗新标准
刘卫平
刘卫平
北京大学肿瘤医院
播放:6
Abstract ID: 7519 Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.
播放:1
Abstract ID: LBA7502 Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MC
刘文扬
刘文扬
国家癌症中心/中国医学科学院肿瘤医院
播放:12
Abstract ID: 4017 Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).
播放:5
Abstract ID: 4016 Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter,
刘秀峰
刘秀峰
东部战区总医院
播放:14
Abstract ID: 4013 Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinic
柳菁菁
柳菁菁
吉林省肿瘤医院
播放:18
Abstract ID: LBA8507 SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-sta
播放:18
Abstract ID: 8505 Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Q

秦叔逵
秦叔逵
东部战区总医院
播放:148
Current Standard Practice after ASCO 2022: 肝癌
邱妙珍
邱妙珍
中山大学附属肿瘤医院
播放:37
抗血管生成联合治疗助力消化道肿瘤患者生存加“优”

S

石焕
石焕
山东省肿瘤医院(山东省肿瘤防治研究院)
播放:50
艾瑞卡®在晚期食管癌一线治疗中的地位与研究探索
斯璐
斯璐
北京大学肿瘤医院
播放:44
中国临床肿瘤学年度进展2021（黑色素瘤）
播放:23
专家评述
宋丽杰
宋丽杰
郑州大学附属第一医院
播放:37
来苏之望，处之泰达---从机制到临床解读索凡替尼新进展
宋玉琴
宋玉琴
北京大学肿瘤医院
播放:12
专家点评
孙恵川
复旦大学附属中山医院
播放:80
晚期肝细胞癌一线系统治疗研究进展-双免篇
孙艳
孙艳
北京大学肿瘤医院
播放:11
Abstract ID: 6002 Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.
播放:3
Abstract ID: 6001 Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.

T

唐玲珑
唐玲珑
中山大学肿瘤防治中心
播放:9
Abstract ID: 6000 Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.

W

 王 峰
郑州大学第一附属医院
播放:65
中国临床肿瘤学年度进展 2021（食管癌）
王峰
中山大学肿瘤防治中心
播放:21
Abstract ID: LBA5 Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
播放:16
Abstract ID: LBA100 Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.
播放:15
Abstract ID: LBA1 Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial
王峰（河南）
王峰（河南）
郑州大学第一附属医院
播放:329
全程获益——速熠素在放化疗科肿瘤患者中的临床获益
王琳琳
王琳琳
山东省肿瘤医院
播放:89
伊鲁阿克•全程护航中国ALK融合基因阳性晚期NSCLC
王启鸣
王启鸣
河南省肿瘤医院
播放:56
长治久“安”—2022ASCO安罗替尼肺癌数据解读
王树森
王树森
中山大学附属肿瘤医院
播放:11
专家评述
王涛
王涛
解放军总医院
播放:17
Abstract ID: LBA1001 Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
播放:7
Abstract ID: LBA3 Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study
王晓稼
王晓稼
浙江省肿瘤医院
播放:13
专家评述
王哲海
王哲海
山东省肿瘤医院
播放:27
Abstract ID:102 Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
播放:17
Abstract ID:9002 KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
播放:12
Abstract ID:8500 Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
吴慧娟
吴慧娟
河南省肿瘤医院
播放:88
晚期NSCLC免疫治疗决策
吴剑挥
吴剑挥
北京大学肿瘤医院
播放:15
Abstract ID: LBA4011 Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
播放:12
Abstract ID: 4008 Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
吴令英
吴令英
中国医学科学院肿瘤医院
播放:106
Current Standard Practice after ASCO 2022: 卵巢癌

X

徐卫
徐卫
江苏省人民医院
播放:6
阿可替尼在CLL中的最新进展

Y

杨帆
杨帆
北京大学人民医院
播放:87
中国临床肿瘤学年度进展2021 （肺癌）
杨宏英
杨宏英
云南省肿瘤医院
播放:43
全程获益——速熠素在手术患者中的临床获益
播放:25
专家评述
杨坤禹
杨坤禹
华中科技大学同济医学院附属协和医院
播放:7
专家评述
杨勇
杨勇
北京大学肿瘤医院
播放:10
专家评述
杨哲
杨哲
山东省立医院
播放:10
艾瑞卡®晚期NSCLC一线全垒打之路
殷咏梅
殷咏梅
江苏省人民医院
播放:121
Current Standard Practice after ASCO 2022: 乳腺癌
于金明
于金明
山东省肿瘤医院
播放:154
播放:12
虞巍
虞巍
北京大学第一医院
播放:12
Abstract ID: 4516 Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
播放:5
Abstract ID: LBA4500 EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study
播放:4
Abstract ID: 4513 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
袁光文
袁光文
中国医学科学院肿瘤医院
播放:18
Abstract ID: 5509 Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
袁瑛
袁瑛
浙江大学医学院附属第二医院
播放:41
专家评述

Z

张力
张力
中山大学肿瘤防治中心
播放:26
专家评述
播放:13
Updates on Abstract 384950: RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for rec
张小田
张小田
北京大学肿瘤医院
播放:56
中国临床肿瘤学年度进展2021 (胃癌)
播放:22
专家评述
张艳桥
张艳桥
哈尔滨医科大学附属肿瘤医院
播放:112
赵磊
赵磊
山东省肿瘤医院
播放:127
从指南更新，洞悉晚期肝细胞癌一线治疗新策略
周军
周军
北京大学肿瘤医院
播放:98
晚期胆道癌系统治疗研究进展
播放:18
Abstract ID: 4009 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
播放:22
Abstract ID: 4006 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
周俊
周俊
上海阿特蒙医院
播放:22
Abstract ID: 4003 Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from
播放:8
Abstract ID: 4001 The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).
朱军
朱军
北京大学肿瘤医院
播放:35
Current Standard Practice after ASCO 2022: 淋巴瘤

首页

视频

会议

我的